X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA AUROBINDO PHARMA AJANTA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 19.8 14.8 133.8% View Chart
P/BV x 4.5 3.8 119.0% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 AJANTA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
AUROBINDO PHARMA
Mar-17
AJANTA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,818895 203.1%   
Low Rs1,106622 177.8%   
Sales per share (Unadj.) Rs239.5254.6 94.1%  
Earnings per share (Unadj.) Rs52.839.3 134.4%  
Cash flow per share (Unadj.) Rs59.546.6 127.8%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs230.0160.0 143.8%  
Shares outstanding (eoy) m88.77585.88 15.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.13.0 204.9%   
Avg P/E ratio x27.719.3 143.4%  
P/CF ratio (eoy) x24.616.3 150.9%  
Price / Book Value ratio x6.44.7 134.1%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m129,782444,390 29.2%   
No. of employees `0006.814.0 48.6%   
Total wages/salary Rs m3,76517,678 21.3%   
Avg. sales/employee Rs Th3,128.410,667.8 29.3%   
Avg. wages/employee Rs Th554.01,264.3 43.8%   
Avg. net profit/employee Rs Th689.71,645.8 41.9%   
INCOME DATA
Net Sales Rs m21,258149,157 14.3%  
Other income Rs m2421,159 20.8%   
Total revenues Rs m21,499150,316 14.3%   
Gross profit Rs m6,58434,343 19.2%  
Depreciation Rs m5964,276 13.9%   
Interest Rs m4667 0.6%   
Profit before tax Rs m6,22630,558 20.4%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5397,597 20.3%   
Profit after tax Rs m4,68623,012 20.4%  
Gross profit margin %31.023.0 134.5%  
Effective tax rate %24.724.9 99.5%   
Net profit margin %22.015.4 142.9%  
BALANCE SHEET DATA
Current assets Rs m12,23692,062 13.3%   
Current liabilities Rs m3,46166,223 5.2%   
Net working cap to sales %41.317.3 238.3%  
Current ratio x3.51.4 254.4%  
Inventory Days Days60106 56.8%  
Debtors Days Days8468 124.8%  
Net fixed assets Rs m11,14062,919 17.7%   
Share capital Rs m177586 30.2%   
"Free" reserves Rs m20,23793,133 21.7%   
Net worth Rs m20,41493,719 21.8%   
Long term debt Rs m101,814 0.6%   
Total assets Rs m24,486162,494 15.1%  
Interest coverage x1,519.446.8 3,246.6%   
Debt to equity ratio x00 2.6%  
Sales to assets ratio x0.90.9 94.6%   
Return on assets %19.214.6 131.5%  
Return on equity %23.024.6 93.5%  
Return on capital %30.532.7 93.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66775,838 15.4%   
Fx outflow Rs m1,61630,224 5.3%   
Net fx Rs m10,05245,613 22.0%   
CASH FLOW
From Operations Rs m2,85432,786 8.7%  
From Investments Rs m-2,604-17,870 14.6%  
From Financial Activity Rs m-2-19,153 0.0%  
Net Cashflow Rs m248-4,239 -5.9%  

Share Holding

Indian Promoters % 73.8 54.1 136.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 8.0 19.5%  
FIIs % 7.6 27.7 27.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.2 166.7%  
Shareholders   20,968 69,601 30.1%  
Pledged promoter(s) holding % 4.4 8.6 51.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DISHMAN PHARMA  CADILA HEALTHCARE  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Pharma & Realty Stocks Gain(09:30 am)

Asian share markets are mixed today. The Nikkei 225 is flat while the Hang Seng is down 0.1%. The Shanghai Composite is trading down by 1.1%.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 20, 2018 10:49 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS